123 related articles for article (PubMed ID: 37824540)
21. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.
Boylan B; Rice AS; Dunn AL; Tarantino MD; Brettler DB; Barrett JC; Miller CH; ;
J Thromb Haemost; 2015 Jan; 13(1):47-53. PubMed ID: 25354263
[TBL] [Abstract][Full Text] [Related]
22. Comparative measurement of FVIII inhibitors in hemophilia A patients using ELISA and the Bethesda assay.
Kim SY; Kang SY; Lee WI
Korean J Lab Med; 2010 Jun; 30(3):260-3. PubMed ID: 20603586
[TBL] [Abstract][Full Text] [Related]
23. Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics.
Kahle J; Orlowski A; Stichel D; Healey JF; Parker ET; Donfield SM; Astermark J; Berntorp E; Lollar P; Schwabe D; Königs C
Haemophilia; 2017 Mar; 23(2):292-299. PubMed ID: 27862687
[TBL] [Abstract][Full Text] [Related]
24. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice.
Qadura M; Waters B; Burnett E; Chegeni R; Hough C; Othman M; Lillicrap D
Haemophilia; 2011 Mar; 17(2):288-95. PubMed ID: 21091850
[TBL] [Abstract][Full Text] [Related]
25. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity.
Towfighi F; Gharagozlou S; Sharifian RA; Kazemnejad A; Esmailzadeh K; Managhchi MR; Shokri F
Acta Haematol; 2005; 114(2):84-90. PubMed ID: 16103630
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of anti-factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents.
Boylan B; Niemeyer GP; Werner B; Miller CH
Haemophilia; 2021 Jan; 27(1):e40-e50. PubMed ID: 33216433
[TBL] [Abstract][Full Text] [Related]
27. Joint bleeds increase the inhibitor response to human factor VIII in a rat model of severe haemophilia A.
Lövgren KM; Søndergaard H; Skov S; Wiinberg B
Haemophilia; 2016 Sep; 22(5):772-9. PubMed ID: 27439658
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
[TBL] [Abstract][Full Text] [Related]
29. Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII.
Hillarp A; Holme PA; Wåland EP; Le MS; Henriksson CE; Tjønnfjord GE; Måseide RJ
J Thromb Haemost; 2023 Oct; 21(10):2771-2775. PubMed ID: 37543216
[TBL] [Abstract][Full Text] [Related]
30. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.
Verbruggen B; van Heerde WL; Laros-van Gorkom BA
Semin Thromb Hemost; 2009 Nov; 35(8):752-9. PubMed ID: 20169511
[TBL] [Abstract][Full Text] [Related]
31. FVIII inhibitors display FV-neutralizing activity in the prothrombin time assay.
Arsiccio A; Beavis J; Raut S; Coxon CH
J Thromb Haemost; 2021 Aug; 19(8):1907-1913. PubMed ID: 33914406
[TBL] [Abstract][Full Text] [Related]
32. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.
Miller CH; Platt SJ; Rice AS; Kelly F; Soucie JM;
J Thromb Haemost; 2012 Jun; 10(6):1055-61. PubMed ID: 22435927
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A- A Systematic Review and Meta-Analysis.
Abdi A; Bordbar MR; Hassan S; Rosendaal FR; van der Bom JG; Voorberg J; Fijnvandraat K; Gouw SC
Front Immunol; 2020; 11():563. PubMed ID: 32457734
[No Abstract] [Full Text] [Related]
34. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation.
Meijer P; Verbruggen B
Semin Thromb Hemost; 2009 Nov; 35(8):786-93. PubMed ID: 20169515
[TBL] [Abstract][Full Text] [Related]
35. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sun J; Hua B; Chen X; Samulski RJ; Li C
Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
[TBL] [Abstract][Full Text] [Related]
36. Antibody response to recombinant human coagulation factor VIII in a new rat model of severe hemophilia A.
Lövgren KM; Søndergaard H; Skov S; Weldingh KN; Tranholm M; Wiinberg B
J Thromb Haemost; 2016 Apr; 14(4):747-56. PubMed ID: 26784374
[TBL] [Abstract][Full Text] [Related]
37. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.
Lin Y; Yang X; Chevrier MC; Craven S; Barrowcliffe TW; Lemieux R; Ofosu FA
Haemophilia; 2004 Sep; 10(5):459-69. PubMed ID: 15357771
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
Amiral J; Seghatchian J
Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
[TBL] [Abstract][Full Text] [Related]
39. Nijmegen-Bethesda assay to measure factor VIII inhibitors.
Duncan E; Collecutt M; Street A
Methods Mol Biol; 2013; 992():321-33. PubMed ID: 23546724
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs.
Martin PG; Sukhu K; Chambers E; Giangrande PL
Clin Lab Haematol; 1999 Apr; 21(2):125-8. PubMed ID: 10342072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
